Improving Dysplasia Detection in Barrett's Esophagus

Erik A. Holzwanger, Alex Y. Liu, Prasad G. Iyer

Research output: Contribution to journalReview articlepeer-review

Abstract

The incidence of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) continues to increase in Western countries, and EAC continues to have an overall 5-year survival rate of less than 20%. This is predominantly due to most EAC cases being diagnosed at advanced stages, after the onset of alarm symptoms. The rationale behind endoscopic surveillance of BE follows the paradigm that metaplasia (BE) progresses to EAC via the development of low- (LGD) and then high-grade dysplasia (HGD). Hence, endoscopic surveillance is recommended to enable early detection of dysplasia and EAC. Numerous endoscopic eradication therapy (EET) modalities, such as radiofrequency ablation (RFA), cryotherapy, and endoscopic resection, enable effective treatment of dysplasia and early-stage EAC. Indeed, randomized trials have conclusively shown that endoscopic treatment of BE-HGD and BE-LGD with RFA reduces progression to EAC. Additionally, EET effectively treats early-stage EAC.

Original languageEnglish (US)
Pages (from-to)157-166
Number of pages10
JournalTechniques and Innovations in Gastrointestinal Endoscopy
Volume25
Issue number2
DOIs
StatePublished - Jan 2023

Keywords

  • Barrett's esophagus
  • Dysplasia
  • Esophageal adenocarcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Improving Dysplasia Detection in Barrett's Esophagus'. Together they form a unique fingerprint.

Cite this